S-1: Tempus AI Files S-1 Registration for Secondary Offering of Class A Common Stock

Tempus AI is registering the resale of up to 4,843,136 shares of Class A common stock by a selling stockholder, REALM IDx, Inc., following the acquisition of Ambry Genetics Corporation.

Summary

• Tempus AI has filed an S-1 registration statement with the SEC to register the resale of up to 4,843,136 shares of its Class A common stock.
• The shares are being offered by REALM IDx, Inc., the selling stockholder, as stock consideration from the acquisition of Ambry Genetics Corporation.
• Tempus AI will not receive any proceeds from the sale of these shares.
• The selling stockholder may offer the shares publicly or through private transactions at prevailing market prices or negotiated prices after any applicable lock-up period expires.
• As of February 24, 2025, the last reported sales price of Tempus AI's Class A common stock was $69.57 per share.
• 2,152,505 of the Shares held by the Seller are subject to a lock-up for a period of one year following the closing date of the Acquisition.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on the technical details of the share registration and sale. It does not contain overtly positive or negative statements about the company's future prospects, but the lack of proceeds to the company is a slight negative.

Positives

• The registration statement allows the selling stockholder to resell the shares of Class A common stock received in the Ambry Genetics acquisition.
• The company is fulfilling its registration obligations under the Securities Purchase Agreement.
• The company's Class A common stock is listed on the Nasdaq Global Select Market under the symbol TEM.

Negatives

• Tempus AI will not receive any proceeds from the sale of shares by the selling stockholder.
• The sale of a large number of shares by the selling stockholder could potentially put downward pressure on the stock price.

Risks

• Investing in Tempus AI's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus and the company's Annual Report on Form 10-K.
• The selling stockholder may sell a significant number of shares, which could negatively impact the stock price.

Future Outlook

The selling stockholder may offer, sell or distribute all or a portion of the Shares publicly or through private transactions at prevailing market prices or at negotiated prices after the expiration of any applicable lock-up period described in this prospectus.

Industry Context

Tempus AI is positioning itself as a leader in precision medicine by combining healthcare expertise with technology capabilities, particularly in AI. The acquisition of Ambry Genetics strengthens its position in genetic testing and data analysis for personalized medicine.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• To make a detailed comparison to industry standards, more information would be needed about Tempus AI's financial performance, growth rate, and market share compared to its competitors.
• Comparable companies in the genomics and precision medicine space include Illumina, Foundation Medicine (Roche), and Guardant Health.
• A comparison would involve analyzing metrics such as revenue growth, gross margin, R&D spending, and market penetration in oncology and other disease areas.

Stakeholder Impact

• Shareholders may experience a dilution of their ownership if the selling stockholder sells a significant portion of the registered shares.
• The acquisition of Ambry Genetics Corporation could benefit employees and customers through expanded services and capabilities.

Next Steps

• The selling stockholder will proceed with the resale of the registered shares.
• Tempus AI will maintain the effectiveness of the registration statement.

Key Dates